Mario Gabelli Reveales Latest Moves In Its Equity Portfolio
Mario Gabelli's fund GAMCO Investors and its affiliates, have revealed in several filings with the SEC, some of the latest moves related to the holdings in its equity portfolio.
Cadence Pharmaceuticals Inc (CADX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 0 | $0 | 0% | |
| 2. | Iguana Healthcare Management Stuart Weisbrod | 0 | $0 | 0% | |
| 3. | Consonance Capital Management Mitchell Blutt | 0 | $0 | 0% | |
| 4. | Springbok Capital Gavin Saitowitz And Cisco J. Del Valle | 0 | $0 | 0% | |
| 5. | Ellington Mike Vranos | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.48 | 16,000 | Officer, Director | 307,500 | 2011-05-17 | Filing | |
| $7.04 | 9,000 | Director | 20,000 | 2011-05-10 | Filing | |
| $7.22 | 2,000 | Officer | 2,000 | 2011-05-10 | Filing | |
| $8.98 | 10,000 | Director | 10,000 | 2010-05-11 | Filing | |
| $7.13 | 3,128,258 | Large Shareholder | 3,128,258 | 2009-02-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.12 | 8,500 | Officer | 5,000 | 2013-12-17 | Filing | |
| $8.76 | 13,014 | Officer | 3,745 | 2013-12-16 | Filing | |
| $9.16 | 7,812 | Officer | 2,000 | 2013-12-02 | Filing | |
| $7.60 | 9,000 | Officer | 5,000 | 2013-11-18 | Filing | |
| $7.20 | 27,000 | Officer | 5,000 | 2013-11-15 | Filing |
News See All
Cadence Pharmaceuticals, Inc. (CADX), Griffin Land & Nurseries, Inc. (GRIF) and Three Other Moves From Mario Gabelli and GAMCO Investors
As usual, Mario Gabelli has been very active this week. His fund, GAMCO Investors, has reported two new positions and has increased its investment in three other companies.
Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Hedge Funds Are Dumping EXACT Sciences Corporation (EXAS)
In the financial world, there are a multitude of gauges shareholders can use to analyze Mr. Market. Two of the most innovative are hedge fund and insider trading interest.
Hedge Funds Are Buying ACADIA Pharmaceuticals Inc. (ACAD)
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Array Biopharma Inc (ARRY): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Halozyme Therapeutics, Inc. (HALO), Viropharma Inc (VPHM): Three Horrendous Health-Care Stocks This Week
One decision led to a double whammy this week for biotech companies Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Viropharma Inc (NASDAQ:VPHM).
Is Merrimack Pharmaceuticals Inc (MACK) Going to Burn These Hedge Funds?
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Hedge Funds Are Dumping Optimer Pharmaceuticals, Inc. (OPTR)
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
Here is What Hedge Funds Think About ACADIA Pharmaceuticals Inc. (ACAD)
To most market participants, hedge funds are viewed as underperforming, outdated financial vehicles of the past.